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Glucose-lowering therapy in
type 2 diabetes
New hope after the EMPA-REG outcome trial
Introduction
The major cause of death and compli-
cations in patients with type 2 diabetes
(T2DM)iscardiovasculardisease(CVD).
More than60%ofall patientswithT2DM
die of CVD, and an even greater percent-
age have serious complications [1].
The impact of glucose lowering on
cardiovascular complications is a world-
wide debated issue. Three major studies
(ACCORD, ADVANCE, and VADT)
evaluated the impact of attaining eug-
lycemia (ACCORD) or near-euglycemia
(ADVANCE, VADT) in older patients
with diabetes and high cardiovascular
(CV) risk [2–4]. None of these studies,
either individually or on pooled analysis,
demonstrated any reduction in all-cause
or CV mortality, although the meta-
analyses revealed 15–17% reductions in
the incidence of non-fatal myocardial
infarction in those exposed to tight glu-
cose control [5]. A higher mortality was
observed in the intensive glucose con-
trol arm of ACCORD, resulting in the
premature termination of the glucose-
lowering component of this study [2].
Also, the occurrence of hypoglycaemic
episodes (total and major) was signif-
icantly higher in the intensive glucose
control arms of all three studies [1].
In addition to hyperglycaemia, patients
withT2DMoftenpresentwith additional
risk factors that predispose them toCVD.
These include insulin resistance, obesity,
hypertension, dyslipidaemia, chronic in-
ﬂammation, platelet abnormalities, and
chronic inﬂammation [6].
Recent dramatic decline of all-
causemortality and CV death in
T2DM
During the last 25 years (1976–2001) an
impressive decline in all-cause (–48 %)
and cardiovascular disease (CVD) mor-
tality (–62 %) rates among both men and
women with diabetes mellitus was ob-
served in the Framingham study versus
the period of 1950–1975 [7]. The imple-
mentation of the multifactorial CV risk
factor management (blood pressure and
lipid lowering) resulted in an enormous
improvement in the prognosis of T2DM
treated in developed nations (US, EU
countries, Canada,Australia). Data from
the Danish National Diabetes Register
showed that the mortality rate of T2DM
patients decreased by 40% from 1997
to 2007 [8]. Similarly, the excess mor-
tality of patients with T2DM in Canada
(Ontario) and in UK (THIN database),
decreased by 44 and 43% respectively
from 1996 to 2009 [9]. In addition data
from Australia showed that the age-
standardized mortality rates decreased
from 9.4 to 5.5 per 1,000 patient years
from 1997–2010 [10]. However, in many
countries both men and women with
T2DM continue to remain at a higher
risk of all-cause and CVD mortality
than those without DM despite risk-re-
duction strategies that include lowering
of cholesterol and blood pressure, and
smoking cessation [11].




Unfortunately, we do not have any long-
termmultifactorial intervention study in
newly diagnosed T2DM patients. A re-
cently published nationwide study [12],
which included 435,369 patients with
T2DM from the Swedish National Dia-
betes Register and for each patient ﬁve
controls randomly selected from the gen-
eral population and matched according
to age, sex, and county (total number of
controls n = 2,117,483), showed that the
excess mortality in T2DM was substan-
tially higher with worsening glycaemic
control, severe renal complications, im-
paired renal function, and younger age.
The included patients had the following
characteristics: mean age 65.8 years,
age at diagnosis of T2DM 60.2 years,
44.9 % women, mean BMI: 29.8 kg/m2
and duration of diabetes 5.6 years. After
a follow-up of 5 years 77,117 of 435,369
patients with T2DM (17.7%) died, as
comparedwith 306,097 of 2,117,483 con-
trols (14.5 %) (adjusted HR, 1.15; 95%
CI 1.14–1.16) [12]. The overall excess
risk of death from any cause was very
low as compared with earlier reports,
when the analysis was adjusted for age
and sex and the excess risk decreased
to 15% when the analysis was further
adjusted for coexisting diseases. The
relatively low mortality in the Swedish
T2DMpatients is probably due to aggres-
sive treatment with statins and blood-
pressuremedications and relatively good
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Fig. 18 aDeathfromanycauseamongpatientswithT2DMversuscontrols inrelationtoageandmean
glycated haemoglobin levels.bCV death amongpatientswith T2DM versus controls in relation to
age andmean glycated haemoglobin levels.p-values for the interaction termbetween time-updated
mean glycated haemoglobin or renal disease status and time-updated age categorieswere less than
0.001 in all models
diabetes control. Mean blood pressure
was 140/78 mmHg, mean HbA1c was
7.1 %, and mean LDL was 2.94 mmol/l.
The excess risk of death ranged from
30–40% among patients 65–74 years
of age, as compared with controls in
the same age group, whereas the ex-
cess mortality was 100–200% among
those younger than 55 years of age, as
compared with controls. Remarkably,
all-cause mortality (. Fig. 1a) and CV
death (. Fig. 1b) were closely related to
glycaemic control (HbA1c) in all age
groups. However, the relationship was
much stronger in younger patients and
less pronounced in elderly patients. Re-
markably, patients 65–74 years of age
with normoalbuminuria and an HbA1c
of ≤ 6.9 % had a lower risk than the
controls. Similarly, the risk was also
lower among patients ≥ 75 years of age
with an HbA1c of ≤ 7.8 % than among
the controls, but the risk was substan-
tially higher among patients younger
than 55 years of age than among the
controls, despite an HbA1c level in the
target range and normoalbuminuria.
Multifactorial risk factor control
is less performed in patients
without CVD
A recent large study [13] including about
860,000 patients assessed the incidence
of major CV hospitalization events and
all-cause deaths among adults with di-
abetes with or without CVD associated
with inadequately controlled diabetes
(HbA1c), high LDL-cholesterol (LDL-
C), high bloodpressure (BP), and current
smoking. Inadequate risk factor control
was classiﬁed as LDL-C ≥ 100 mg/dl,
HbA1c > 7%, BP ≥ 140/90 mmHg, or
smoking. Interestingly, compared with
those without baseline CVD, those with
baselineCVDhadbetter controlof smok-
ing (8.0 vs. 9.8 %), HbA1c ≥ 7% (42 vs.
53%), and LDL-C ≥ 100 mg/dl (38 vs.
58%), and they had similar proportions
of subjects with systolic/diastolic BP
≥ 140/90 mmHg (23 vs. 21%). Mean
age at baseline was 59 years; 48% of
subjects were female, 45% were white,
and 31% had CVD. Mean follow-up
was 59 months. Major CV events were
based on primary hospital discharge di-
agnoses for myocardial infarction (MI)
and acute coronary syndrome (ACS),
stroke, or heart failure (HF). Event rates
per 100 person-years for adults with
diabetes and CVD versus those without
CVD were 6.0 vs. 1.7 for MI/ACS, 5.3
vs. 1.5 for stroke, 8.4 vs. 1.2 for HF, 18.1
vs. 40 for all CV events, and 23.5 vs. 5.0
for all-cause mortality. The percentages
of CV events and deaths associated with
inadequate risk factor control were 11
and3%, respectively, for thosewithCVD
but 34 and 7%, respectively, for those
without CVD. These data demonstrate
that (a) T2DM patients without CVD
are not as well treated for risk factor
control and (b) that the inadequate risk
factor control in patients without CVD
has a very negative impact on CV events
and death.
CV outcome studies with novel
anti-diabetic agents in patients
with T2DM
Due to the close association of CVDwith
T2DM and the uncertainty about the
CV safety of glucose-lowering drugs, the
Food and Drug Administration issued
in 2008 guidance for the demonstration
of CV safety for new anti-diabetes drugs
[14].
. Fig. 2 summarizes all CV outcomes
trials (CVOT), which will be available
at the end of the year 2020). At that
time all available CVOT studies will in-
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clude about 180,000 patients with T2DM
and CVD followed up with a novel anti-
diabetic drug or placebo in addition to
standard care. In the mean time we have
for most of the newer glucose-lowering
drugs results from CVOT, the PROac-
tive study [15] for pioglitazone, the ORI-
GIN study [16] for Insulin Glargine, the
SAVOR study [17] for Saxagliptin, EX-
AMINE for Alogliptin [18], TECOS for
Sitagliptin [19] and ELIXA for Lixise-
natide [20]. The design of these stud-
ies makes it almost impossible to show
beneﬁts of any novel drug. All patients
were at high CV risk and had long-stand-
ing uncontrolled T2DM for 8–10 years.
Treatments that might be eﬀective for the
primary preventionofCVDandhave po-
tential CV beneﬁts in early intervention
may be ineﬀective in the progressed stage
ofT2DM. Inaddition, most patientswere
receiving standard care treatments for
their CVD (antiplatelet agents, including
aspirin, 75–97%; statins, 78–90%; beta-
blockers, 62–85%; angiotensin convert-
ing enzyme inhibitor/ angiotensin recep-
tor blocker, 79–85%) so that any po-
tential added CV risk reduction or sec-
ondary CVD prevention by a novel anti-
diabetic drug was less likely to be ob-
served. The published results show that
most agents, with the exception of pi-
oglitazone and empagliﬂozin, neither in-
creased nor decreasedmajor adverse CV
events (CV death, non-fatal myocardial
infarction, and non-fatal stroke) com-
pared with placebo (. Table 1).
Remarkably, a signiﬁcant and simi-
lar reduction of the three-point MACE
(CV death, non-fatal MI, and non-fatal
stroke)was found in [15] for pioglitazone
(HR0.84; 95%CI0.72–0.98)and forEm-
pagliﬂozin (HR 0.86; 95% CI 0.74–0.99)
in the EMPA-REG outcome study [21],
however with striking diﬀerences. In
PROactive [15]both fatal/nonfatal stroke
(HR = 0.72, p = 0.045) and fatal/nonfatal
myocardial infarction (HR = 0.53, p =
0.008) were markedly reduced, whereas
the small reduction of MI and the in-
crease of stroke in EMPA-REG outcome
[21] did not reach levels of signiﬁcance.
By contrast the impressive reduction of
CV death and all-cause mortality seen
in patients exposed to empagliﬂozin was
not seen with pioglitazone.
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Abstract
Prevention of cardiovascular morbidity
and mortality remains the key factor in
the treatment of type 2 diabetes (T2DM).
In the early phase of T2DM, multifactorial
intervention is mandatory and glucose
levels should be near normal, in particular in
younger patients presenting with the highest
cardiovascular risk. Anti-diabetic drugs
without any risk for hypoglycaemia should
be preferred in order to reduce clinical inertia
and increase the long-term adherence to the
treatment. In patients already presentingwith
cardiovascular disease, the best outcomemay
be expected with the triple oral therapy of
metformin, pioglitazone, and empagliﬂozin,
although a controlled prospective study
versus insulin therapy is needed to conﬁrm
the expectation.
Keywords
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Glukosesenkende Therapie bei Typ-2-Diabetes. Neue Hoﬀnung
nach der EMPA-REG-Wirkungsstudie
Zusammenfassung
Die Verhinderung kardiovaskulärer Ereignisse
und des kardiovaskulären Todes bleiben die
Schlüsselfaktoren bei der Behandlung des
Typ-2-Diabetesmellitus. In der Frühphase des
Diabetes ist eine multifaktorielle Intervention
notwendig und der Blutzuckerspiegel sollte
annähernd normal sein, besonders bei jungen
Patientenmit hohem kardiovaskulären Risiko.
Antidiabetika ohne Hypoglykämierisiko
sollten bevorzugt warden, um klinische
Untätigkeit zu reduzieren und die Langzeitad-
härenz der Therapie zu erhöhen. Bei Patienten
mit bereits vorhandener kardiovaskulärer
Erkrankung wird die beste Wirkung mit
einer oralen Tripeltherapie aus Metformin,
Pioglitazone und Empagliﬂozin erwartet,
wiewohl eine kontrollierte prospektive Studie
mit diesen drei Substanzen im Vergleich zu
einer Insulintherapie benötigt wird, um diese
Erwartung zu bestätigen.
Schlüsselwörter
Kardiovaskuläre Erkrankungen · EMPA-REG-
Outcome-Studie · PROactive · Antidiabetische
Therapie · Typ-2-Diabetes
PROactive
The PROactive study [15] was a large
prospective, randomized, double-blind,
secondary prevention study that in-
vestigated the eﬀects of pioglitazone
(45mg/day) onmacrovascular outcomes
in 5,238 patients with T2DM and pre-
existing CVD: ~ 50% with previous MI,
25%with previous stroke, and 25%with
peripheral arterial disease (PAD). Treat-
ment with pioglitazone or placebo was
administered in addition to optimized
standard care, which included glucose
lowering, antihypertensive, lipid-alter-
ing, andantithromboticdrugs. Although
the primary end point – a composite
of all-cause mortality, non-fatal MI,
acute coronary syndrome, stroke, ma-
jor leg amputation, and coronary or
leg revascularization – showed only
a nonsigniﬁcant 10% reduction in the
pioglitazone arm, a signiﬁcant reduction
in a composite end point, comprisingCV
death plus non-fatal MI plus non-fatal
stroke, was observed (HR 0.82 [95% CI
0.70–0.97]) in the 3-year follow-up pe-
riod [15]. Furthermore, in patients with
a previous MI, pioglitazone signiﬁcantly
reduced the risk of subsequent MI by
28% and acute coronary syndrome by
38% [22]. In patients with a previous
stroke, pioglitazone decreased chances
of a second stroke by 48% [23], whereas
in patients with PAD no beneﬁcial eﬀect
of pioglitazone could be noted [24]. It is
well known that diabetic patients with
chronic kidney disease (CKD) are at
210 Herz 3 · 2016
Fig. 28 CVoutcomestudies inpatientswithT2DM:chronologyofcompletiondates.(https://clinicaltrials.gov/ct2/home; last
accessedMay29,2015)(SAVOR-TIMI53,NCT01107886;EXAMINE,NCT00968708;ELIXA,NCT01147250;TECOS,NCT00790205;
EMPA-REG-OUTCOME, NCT01131676; LEADER, NCT01179048; SUSTAIN 6, NCT01720446; CANVAS-R, NCT01989754;
ACE, NCT00829660 (*https://www.dtu.ox.ac.uk/ace/; last accessedMay 29, 2015); CARMELINA, NCT01897532; EXSCEL,
NCT01144338;CANVAS,NCT01032629;CAROLINA,NCT01243424;DEVOTE,NCT01959529;TOSCA.IT,NCT00700856;REWIND,
NCT01394952; DECLARE-TIMI 58, NCT01730534; CREDENCE, NCT02065791; NCT01986881)
particularly high risk of CVD. In a post
hoc analysis from PROactive, the ef-
fect of pioglitazone versus placebo was
determined in patients with CKD [25].
Patients treated with pioglitazone were
less likely to reach the composite (all-
cause mortality, MI, or stroke) end point
(HR 0.66 [95% CI 0.45–0.98]) com-
pared with placebo. In addition, two
randomized head-to-head trials with
glimepiridehave shown that pioglitazone
signiﬁcantly decreased the rate of carotid
intima thickness, a surrogate marker of
coronary atherosclerosis [26] and slowed
the progression of coronary atheroscle-
rosis measured by IVUS [27]. The anti-
atherogenic eﬀect of pioglitazone may
be mediated by the improvement of
many CV risk factors [28, 29], such as
increase in HDL-cholesterol, decline of
triglycerides and free fatty acids (FFA),
conversion of small dense LDL particles
to larger, more buoyant, less atherogenic
ones; improvement of endothelial dys-
function; increase of adiponectin and
reduction of PAI-1, CRP, and TNFα,
and reduction of insulin resistance and
visceral fat.
The clinical use of pioglitazone is lim-
ited by the risk of adverse events, includ-
ingweight gain, ﬂuid retention, CHF and
bone fractures [30]. In the PROactive
study [15] 5.7 and 4.1 % of pioglitazone
and placebo patients, respectively, were
admitted to hospital [31]; however, mor-
tality rates due to CHFwere similar (0.96
vs. 0.84%; p = NS). Interestingly, fewer
pioglitazone patients with serious CHF
had a combined end point of death, MI,
or stroke comparedwith placebopatients
(34.9 vs. 47.2 %; p = 0.025). Since heart
failure is an ominous sign in T2DMwith
a ﬁve-year mortality of ~ 50%, it is un-
likely that these individuals really had
CHF. It is more likely that they had ﬂuid
retention and oedema secondary to the
sodium retention eﬀect of pioglitazone in
the kidney. Concern about bladder can-
cer with pioglitazone has been negated
by the results of a 10-year prospective
Kaiser-Permanente Northern-California
study [32]. In that safety study involv-
ing 193,099 T2DM patients, no associa-
tion was found between bladder cancer
risk and use of pioglitazone, including
duration of pioglitazone use, cumulative
pioglitazone dose, or time since initi-
ation of pioglitazone. A further study
[33] including 1.01 million T2DM pa-
tients with over 5.9 million person-years
from six populations, reported no in-
creased risk for bladder cancer either for
pioglitazone (HR= 1.01) or rosiglitazone
(HR = 1.00).
EMPA-REG outcome
The recently published EMPA-REG out-
come trial [21] is an international,
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Table 1 Eﬀect of glucose-lowering drugs on the combined endpoint of CVmortality, non-fatal
myocardial infarction and stroke
Study Anti-diabetic Drug HR p-value
PROACTIVE Pioglitazone 0.84 (CI 0.72–0.98) 0.02
ORIGIN Insulin Glargine 1.02 (CI 0.94–1.11) NS
SAVOR Saxagliptin 1.00 (CI 0.89–1.12) NS
EXAMINE Alogliptin 0.96 (CI 0.80–1.15) NS
CANVAS Canagliﬂozin 1.00 (CI 0.72–1.39) NS
ELIXA Lixisenatide 1.02 (CI 0.89–1.17) NS
TECOS Sitagliptin 0.98 (CI 0.89–1.08) NS
EMPA-REG Empagliﬂozin 0.86 (CI 0.74–0.99) 0.038
HR hazard ratio, CI confidence interval, NS not significant
prospective, placebo-controlled clini-
cal trial investigating the cardiovascular
outcomes of empagliﬂozin, an inhibitor
of sodium-glucose cotransporters type 2
(SGLT2), in patients with T2DM and
known CVD. It is the ﬁrst study to doc-
ument that a glucose-lowering drug can
reduce cardiovascular events in patients
withT2DM. In 7020T2DMpatientswith
a history of CVD, empagliﬂozin reduced,
after a median of 3.1 years, the primary
MACE endpoint (CV death, non-fatal
MI, non-fatal stroke) by 14 % (HR= 0.86,
p = 0.04) and hospitalization for heart
failure by 35% (HR = 0.65, p = 0.002).
A striking diﬀerence was observed be-
tween the threeMACEendpoints: (a) for
CV death, the HR (0.62) was decreased
signiﬁcantly by 38%, (b) for non-fa-
tal MI, the HR (0.87) was decreased
slightly, but not signiﬁcantly (p = 0.22)
and (c) for stroke, the HR (1.24) was
increased modestly, but not signiﬁcantly
(p = 0.22). . Fig. 3 shows the impressive
eﬀects of empagliﬂozin on the absolute
risk reductionofCVevents in theEMPA-
REG outcome study. The reduction in
CV death (5.9 to 3.6 %, p < 0.001) was
observed across all diagnostic categories
(sudden death, 1.6 to 1.1 %; worsening
heart failure, 0.8 to 0.2 %; acute MI, 0.5
to 0.3 %; stroke, 0.5 to 0.3 %; “other CV
death”, 2.4 to 1.6 %). The latter category
includes deaths that cannot be explained
by any other known cause. The reduc-
tion in mortality appeared very early
(< 3 months) and was observed in all
subgroups, without any obvious het-
erogeneity. This reduction in mortality
does not seem to be fully explained by
the concomitant slight reductions in
HbA1c, body weight, waist circumfer-
ence, blood pressure, and serum uric
acid levels in the empagliﬂozin groups
versus the placebo group. The rapid
reduction of mortality in empagliﬂozin-
treated patients suggests a hemodynamic
mechanism of action. The baseline BP
(135.5/76.7 mmHg) was signiﬁcantly
reduced at 4 months (~ 5/2.5 mmHg),
and temporarily correlated with the re-
duction in CV death and hospitalization
for heart failure. A recent study [34]
showed that empagliﬂozin reduced not
only BP but had also favourable eﬀects
on markers of arterial stiﬀness and vas-
cular resistance. The observation that
empagliﬂozin has an impact on the vas-
culature without increasing pulse rate
is interesting from a CV perspective
and could be interpreted as a conse-
quence of a relative reduction in the
sympathetic nervous system tonus. It
seems likely that the beneﬁcial eﬀects
of empagliﬂozin to reduce CV risk and
heart failure are related to the drug’s
hemodynamic/cardiovascular action to
reduce BP and intravascular volume,
resulting in combined afterload and
preload reduction.
Surprisingly, an impressive renopro-
tection was also observed [35] although
26% of the patients with CVD also had
CKD (eGFR < 60), usually not receiving
SGLT2 inhibitors. New onset or wors-
ening kidney disease were reduced by
39%, new macro-albuminuria by 38%,
doubling of serum creatinine by 44%,
and incidence of end-stage renal disease
by 55%. It is important to mention that
themajorityofpatientswithCKDatbase-
line had stage 3a (68%), whereas stage 3b
existed in 32%, furthermore all patients
with CKD stages 4 and 5 were excluded
from the EMPA-REG outcome study.
The EMPA-REG study also conﬁrms
the excellent safety proﬁle of the SGLT2
inhibitor (SGLT2i) class of anti-diabetic
agents. Empagliﬂozin signiﬁcantly re-
duced HbA1c, body weight, waist cir-
cumference, and blood pressure with-
out change in heart rate. There was
no increase in the incidence of hypogly-
caemia despite half of the patients were
pre-treated with insulin, renal impair-
ment, urinary tract infections, volume-
related side eﬀects, bone fractures, or
thromboembolic events. Furthermore,
the rate of hyperglycaemic or normo-
glycaemic diabetic ketoacidosis was very
low and not higher in patients exposed
toempagliﬂozin (0.035%)versusplacebo
(0.020%). Serious adverse events andad-
verse events leading to drug discontinu-
ation were slightly, although not signiﬁ-
cantly lower in the empagliﬂozin group.
As expected, the incidence of genital in-
fections was higher in the empagliﬂozin
group (6.4 %) vs. placebo (1.8 %).
Individualization of anti-
diabetic therapy in relation to
stage of the disease and co-
morbidity
The ADA-EASD consensus statement
published in 2009 [36] advocated initial
treatment with metformin monotherapy
and lifestyle modiﬁcation, followed by
additionof basal insulin or a sulfonylurea
if glycaemic goals are not met (tier 1
recommendations). All other glucose-
lowering therapies were relegated to
a secondary (tier 2) status and only rec-
ommended for selected clinical settings.
The approach that all patients should
have the same HbA1c target (< 7.0 %)
and that all patients should follow an
identical treatment algorithm was heav-
ily criticised by an international expert
group [37]. We argued for an appropriate
selection of anti-diabetic drugs to indi-
vidualise and optimise care with a view
to sustained control of blood glucose and
reduction both of diabetes complications
and CV risk. In addition, we stated that
diabetes guidelines might need revision
to deﬁne a minimum HbA1c value, es-
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Fig. 39 Signiﬁcant Im-





pecially for patients with long-standing
diabetes or established CVD. The ADA-
EASD consensus statements 2012 [38]
and 2015 [39] included most of our
proposals.
Patients not presenting with vas-
cular complications should have near-
normoglycaemic control in association
with strict CVD risk factor control as
documented in the recently published
Swedish population study [12]. In par-
ticular, younger patients with a poor
long-term risk need HbA1c target levels
< 6.5 %, which can be reached when
glucose-lowering drugs are selected not
inducing hypoglycaemia or weight gain.
Metformin remains the optimal drug for
monotherapy, its low cost, proven safety
record, weight reduction or neutrality
and possible beneﬁts on cardiovascular
outcomes have secured its place as the
favoured initial drug choice [40–42].
In second line, DPP-4 inhibitors are
now widely used, since these drugs are
well tolerated by the majority of pa-
tients, even in the elderly and renal-
impaired patients [43–46]. DPP-4 in-
hibitors improve glycaemic control with
similar eﬃcacy to sulphonylurea, but
do not usually provoke hypoglycaemia
or weight gain, are relatively free from
adverse eﬀects, and have recently been
shown not to increase CV risk in large
prospective safety trials. Because of these
factors, DPP-4 inhibitors have become
an established therapy for T2DM and
are increasingly being positioned earlier
in treatment algorithms [39]. When
sulfonylureas are used with respect to
very low cost, Gliclazide should be pre-
ferred versus other sulfonylureas based
on the lower risk for hypoglycaemia and
better CV safety proﬁle [47–50]. The
glucose-lowering potency is very similar
for most of the anti-diabetic drugs when
starting at a HbA1c level of about 8%
[51], however when HbA1c values are
higher Insulin, GLP-1 receptor agonists,
or SGLT2-inhibitors are more powerful
than DPP-4 inhibitors and sulfonylureas
[52–54].
In T2DM patients already presenting
with CVD, principally all drugs (DPP-4
inhibitors, GLP-1 receptor agonists, and
basal insulin glargine) with conﬁrmed
safety in outcome studies [16–20] could
be used, however in order to reduce CV
events and CV death, a combination of
drugs should be preferred with docu-
mented CV beneﬁt. The triple combi-
nation of metformin, pioglitazone, and
empagliﬂozin seems to be at the moment
the best option (. Table 2) to reduce the
high risk for recurrentmyocardial infarc-
tion, acute coronary syndrome or stroke
inpatientswith ahistoryofCVD[22, 23].
In addition, such a combination would
result in reduction of CV death and all-
cause mortality by about one third [21].
This triple combination would be very
eﬀective in lowering HbA1c by diﬀerent
mechanisms – reduction of hepatic glu-
cose production, improvement of insulin
sensitivity and by the glucoretic eﬀect
[54–58] – but not inducing any risk of
hypoglycaemia and oﬀering weight neu-
trality. The profound eﬀect of lower-
ing of both BP and albuminuria – me-
diated by diﬀerent mechanism – may
be helpful to reduce the vascular bur-
den of the high risk patients [41, 42, 58,
59]. This triple combination could also
be used in patients with CKD stages 3
and 4, since a signiﬁcant reduction of
CVevents/mortalitywasdocumented for
all three compounds, for metformin [60,
61], pioglitazone [25], and empagliﬂozin
[35]. In the presence of heart failure
pioglitazone has to be stopped [31], al-
though the well-known water retention
eﬀect of pioglitazone may be neutralized
by empagliﬂozin (. Table 2). . Table 2
shows that (a) some positive or negative
eﬀects of the three individual drugs may
be neutralized in combination; and (b) in
addition some positive eﬀects could also
work synergistically. Unfortunately, no
studywill ever be done to prove our treat-
mentconceptfordiabeticpatientsalready
presenting with CVD. Since in some but
not in all studies DPP-4 inhibitors were
associated with an increased the risk for
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Table 2 Anticipated combinatory eﬀect ofmetformin, pioglitazone, and empagliﬂozin




↓ ↔ ↓↓ ↓↓↓
All-cause death ↓ ↔ ↓↓ ↓↓↓
Myocardial
infarction
↓ ↓ ↔ ↓↓
Stroke ↓ ↓ ↔ ↓↓
Peripheral arterial
disease
↓ ↔ ↔ ↓
Fluid retention ↔ ↑ ↓ ↔
Heart failure ↔ ↑ ↓ ↔
Weight ↓ ↑ ↓ ↓
Blood pressure ↔ ↓ ↓ ↓↓
HbA1c ↓ ↓ ↓ ↓↓↓
LDL-cholesterol ↓ ↔ ↑ ↔
HDL-cholesterol ↔ ↑ ↑ ↑↑
Albuminuria ↔ ↓ ↓ ↓↓
Insulin sensitivity ↑ ↑↑ ↑ ↑↑↑↑
↓ lowered, ↑ elevated,↔ unchanged
heart failure [62–66], these compounds
mayalsonot beused inpatientswith con-
comitant occurrence of CVD and heart
failure. A recent study showed that the
risk for heart failure is particularly high
in the presence of CKD [67], thus pa-
tients with CVD, CKD and heart failure
should be treated with SGLT2 inhibitors
but not with DPP-4 inhibitors [66].
In summary, prevention of CV mor-
bidity and mortality remains to be the
key factor in the treatment of T2DM.
In the early phase of T2DM multifacto-
rial intervention is mandatory and glu-
cose levels should be near normal, in
particular in the younger patients pre-
senting with the highest long-term CV
risk. Anti-diabetic drugs without any
risk for hypoglycaemia should be pre-
ferred in order to reduce clinical inertia
and increase long-term adherence to the
treatment. Two very recent studies [68,
69] are not in favour of a wide use of
sulfonylureas or insulin. In a nationwide
study [68]usingTaiwan’sNationalHealth
Insurance Research Database, DPP-4 in-
hibitors were associated with lower risks
for all-cause death (HR 0.63 [95% CI
0.55–0.72]), MACE (HR, 0.68 [95 %CI
0.55–0.83]), ischemic stroke (HR, 0.64
[95 %CI 0.51–0.81]), and hypoglycaemia
(HR, 0.43 [95%CI 0.33–0.56]) compared
with sulfonylureas as add-on therapy to
metformin but had no eﬀect on risks
for myocardial infarction and hospital-
ization for heart failure. A recent meta-
analysis [69] of randomized controlled
trials evaluating the eﬀects of insulin ver-
susoralhypoglycaemicagents(OHAs)on
all-cause mortality and CV outcomes in
patientswithT2DMdidnot showany su-
periority for insulin therapy concerning
all-cause mortality (RR = 1.00; 95% CI
0.93–1.07), CVdeath (RR=1.00; 95%CI
0.91–1.09), myocardial infarction (RR =
1.04; 95% CI 0.93–1.16), angina (RR =
0.97; 95% CI 0.88–1.06), sudden death
(RR = 1.02; 95% CI 0.66–1.56), or stroke
(RR=1.01; 95%CI0.88–1.15). However,
insulin reduced the risk of heart failure
compared with OHAs (RR = 0.87; 95%
CI 0.75–0.99). In the very high risk sub-
group of secondary prevention of CVD
insulin did not diﬀer from OHAs in all-
cause mortality, CV death, myocardial
infarction, or stroke.
In patients presenting with CVD the
best outcome may be expected with the
tripleoral therapyofmetformin, pioglita-
zone and empagliﬂozin, although a con-
trolled prospective study versus insulin
therapy is needed to conﬁrm the expec-
tation.
Our recommendation for the inclu-
sion of pioglitazone in the triple therapy
indiabetic patientswith a history ofCVD
is strongly supported by recent ﬁndings
of the IRIS study [70, 71], where piogli-
tazone or placebo were added to non-
diabetic patients after ischaemic stroke
or TIA. After a treatment period of 4.8
years pioglitazone prevented stroke or
myocardial infarction by 24 % relative
risk reduction and by 2.9 % absolute risk
reduction (p<0.007), despite the fact that
the patients were well treated according
to current guidelines (antiplatelet drugs
in 95 %, statins in 82 %); blood pressure
values were 133/79 mmHg and LDL val-
ues 89 mg/dl. In the insulin-resistant
nondiabetic patients diabetes developed
in 7,7 % of the patients receiving placebo,
but in only 3.8 % under pioglitazone (58
% relative risk reduction, p < 0.001). In-
cidence ofheart failure or incident cancer
were not increased in patients receiving
pioglitazone, but there was more weight
gain (plus 3 kg) and bone fractures under
pioglitazone compared with placebo (5.1
vs. 3.2 %, p = 0.01). Since two thirds of
nondiabetic patients with CVD and al-
most all patients with overt diabetes are
insulin resistant, these data show for the
ﬁrst time that a therapy directed to in-
sulin resistance can prevent cardiac and
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